Skip to content

As Full Disclosure Nears, Doctors’ Pay for Drug Talks Plummets

As transparency increases and blockbuster drugs lose patent protection, drug companies have dramatically scaled back payments to doctors for promotional talks. This fall, all drug and medical device companies will be required to report payments to doctors.

Loeb & Loeb LLP is noted and Scott Liebman is quoted on the impact of the Physician Payment Sunshine Act, a part of the 2010 health reform law. 

To read the full article, click here

A version of this article also appeared on NPR.